Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR

[1]  V. Kuchroo,et al.  TIGIT predominantly regulates the immune response via regulatory T cells , 2024, The Journal of clinical investigation.

[2]  Yanfeng Gao,et al.  A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses , 2020, Acta pharmaceutica Sinica. B.

[3]  Young Hak Kim,et al.  Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab , 2019, Scientific Reports.

[4]  D. Vignali,et al.  Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups , 2019, Nature Immunology.

[5]  Yuzhen Wang,et al.  Anticancer activity of emodin is associated with downregulation of CD155. , 2019, International immunopharmacology.

[6]  A. Kulkarni,et al.  Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma , 2019, Cancer Immunology Research.

[7]  I. Benhar,et al.  Immune checkpoint inhibitor combinations: Current efforts and important aspects for success. , 2019, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[8]  Xiangguo Duan,et al.  Use of aspirin in the prevention of colorectal cancer through TIGIT‐CD155 pathway , 2019, Journal of cellular and molecular medicine.

[9]  O. Ashur-Fabian,et al.  Thyroid Hormones and Cancer: A Comprehensive Review of Preclinical and Clinical Studies , 2019, Front. Endocrinol..

[10]  Xiaoye Zhang,et al.  Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors , 2019, Oncology letters.

[11]  J. Chisholm,et al.  The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves , 2019, The Journal of Immunology.

[12]  Yanfeng Gao,et al.  Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells , 2018, Front. Immunol..

[13]  Lieping Chen,et al.  A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization , 2018, Cell.

[14]  M. Ramachandra,et al.  Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways , 2018, BioDrugs.

[15]  Huan Wang,et al.  Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity , 2018, Nature Immunology.

[16]  Baobiao Zhuo,et al.  Overexpression of CD155 relates to metastasis and invasion in osteosarcoma. , 2018, Oncology letters.

[17]  Z. Qian,et al.  Photosensitizer Micelles Together with IDO Inhibitor Enhance Cancer Photothermal Therapy and Immunotherapy , 2018, Advanced science.

[18]  Xinlin Chen,et al.  CD155T/TIGIT Signaling Regulates CD8+ T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer. , 2017, Cancer research.

[19]  Jun S. Liu,et al.  TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. , 2017, Cancer research.

[20]  K. Excoffon,et al.  Poliovirus Receptor: More than a simple viral receptor. , 2017, Virus research.

[21]  Huanling Zhang,et al.  High-affinity human PD-L1 variants attenuate the suppression of T cell activation , 2017, Oncotarget.

[22]  J. Kirchmair,et al.  Data Resources for the Computer-Guided Discovery of Bioactive Natural Products , 2017, J. Chem. Inf. Model..

[23]  Wei Wang,et al.  CD155 knockdown promotes apoptosis via AKT/Bcl‐2/Bax in colon cancer cells , 2017, Journal of cellular and molecular medicine.

[24]  A. Ribas,et al.  Combination cancer immunotherapies tailored to the tumour microenvironment , 2016, Nature Reviews Clinical Oncology.

[25]  Jianjian Peng,et al.  A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. , 2016, International immunopharmacology.

[26]  Lei Liu,et al.  Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy. , 2015, Angewandte Chemie.

[27]  Axel Hoos,et al.  Big opportunities for small molecules in immuno-oncology , 2015, Nature Reviews Drug Discovery.

[28]  J. Hackney,et al.  The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. , 2014, Cancer cell.

[29]  C. Li,et al.  Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells , 2012, Cell Death and Differentiation.

[30]  Jianping Yin,et al.  Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell–cell adhesion and signaling mechanism that requires cis-trans receptor clustering , 2012, Proceedings of the National Academy of Sciences.

[31]  T. Barrette,et al.  Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. , 2007, Neoplasia.

[32]  D. Louis,et al.  CD155/PVR plays a key role in cell motility during tumor cell invasion and migration , 2004, BMC Cancer.

[33]  L. Moretta,et al.  Identification of PVR (CD155) and Nectin-2 (CD112) as Cell Surface Ligands for the Human DNAM-1 (CD226) Activating Molecule , 2003, The Journal of experimental medicine.

[34]  E. Wimmer,et al.  Poliovirus can enter and infect mammalian cells by way of an intercellular adhesion molecule 1 pathway. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[35]  E. Wimmer,et al.  Cellular receptor for poliovirus: Molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily , 1989, Cell.

[36]  Yanfeng Gao,et al.  In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1. , 2019, Methods in enzymology.

[37]  E. Chiang,et al.  TIGIT: A Key Inhibitor of the Cancer Immunity Cycle. , 2017, Trends in immunology.

[38]  R. Scolyer,et al.  Resistance to PD1/PDL1 checkpoint inhibition. , 2017, Cancer treatment reviews.

[39]  Y. Kawakami,et al.  Melanoma Cells Control Anti-Melanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase. , 2015, The Journal of investigative dermatology.

[40]  H. Clark,et al.  The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells , 2009, Nature Immunology.

[41]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..